MacroGenics is a leader in the discovery and development of innovative medicines that utilize our next generation antibody-based technologies. Our team of 150+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases. Our products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe.

Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.

The employees at MacroGenics are committed to our mission of delivering life-changing medicines to patients. We leverage our world-class capabilities in biologic discovery, development and production to create novel product candidates that are highly differentiated and which are intended to address areas of significant unmet clinical need.

We embrace this mission recognizing its boldness and appreciating the challenges that incumbents in the industry have faced. The discovery and development of novel therapeutics is a process that has historically been characterized by long development timelines, significant investment, high rates of program failure and increasingly stringent requirements by both payors and regulators.

We believe our approach to product development is a unique source of competitive advantage. Our product development model has been constructed with three fundamental goals: identifying the right product candidates early, moving these product candidates quickly through the development process, and always maintaining a keen awareness of the need for improved health outcomes for patients.